Medpage Today on MSN14h
Risk-Reducing Surgery May Benefit BRCA Carriers With Early-Onset Breast Cancer
Among more than 5,000 patients followed for a median of roughly 8 years, bilateral risk-reducing mastectomy (RRM) was ...
Cancer therapy shows long-term survival benefits for patients with high-risk, BRCA-positive breast cancer in trial
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to ...
BRCA-mutation carriers with history of early-onset breast cancer may benefit from risk-reducing surgery
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral ...
LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial
AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term results ...
Armed robbery in Revesby1d
PARP Inhibitors Boost Survival in High-Risk BRCA Breast Cancer
Patients with high-risk, BRCA-positive breast cancer who received olaparib after standard treatment continued to have better ...
News Medical1d
Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...
Armed robbery in Revesby1d
Surgery May Benefit BRCA Carriers With Early Breast Cancer
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral ...
News Medical1d
Risk-reducing surgeries provide benefits for young BRCA-mutation carriers
Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...
Late-stage breast cancer is rising, especially among Black women
The rates of late-stage breast cancer at diagnosis have risen among women in all racial and ethnic groups, but Black women ...
Pharmabiz2h
AstraZeneca & Merck announce OlympiA phase 3 trial of Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer
AstraZeneca & Merck announce OlympiA phase 3 trial of Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer: Rahway, New Jersey Friday, Dec ...